Dr. Reddy's Q2 FY26 results

Europe Segment (Q2 FY26) Q2 FY26 Revenues: ₹1,380 crore Year-on-Year (YoY) Growth: 138% Quarter-on-Quarter (QoQ) Growth: 8% Main Driver of Growth: The acquired Consumer Healthcare portfolio in Nicotine Replacement Therapy (NRT). Growth Excluding NRT: 17% YoY and 12% QoQ. H1 FY26 Revenues: ₹2,650 crore (up 140% YoY). Key Countries Q2 FY26 Contribution: Germany: ₹400 crore (+23% YoY, +26% QoQ) UK: ₹160 crore (-4% YoY, -10% QoQ) Rest of Europe: ₹120 crore (+35% YoY, +6% QoQ) New Products Launched in Q2 FY26: 8 India Segment (Q2 FY26) Q2 FY26 Revenues: ₹1,580 crore Year-on-Year (YoY) Growth: 13% Quarter-on-Quarter (QoQ) Growth: 7% H1 FY26 Revenues: ₹3,050 crore (up 12% YoY). Drivers of Growth: Price increases, new launches, and higher volumes. New Brands Launched in Q2 FY26: 11 (taking the H1 total to 16)The user has provided a detailed text on Dr. Reddy's Q2 FY26 results. The question implicitly asks for the performance details of the Europe and India segments from the provided text. No external search is required. Europe Segment Performance (Q2 FY26): Q2 FY26 Revenues: ₹1,380 crore YoY Increase: 138% QoQ Increase: 8% Primary Driver: Mainly driven by the Nicotine Replacement Therapy (NRT) portfolio. Growth Excluding NRT: 17% YoY and 12% QoQ. H1 FY26 Revenues: ₹2,650 crore (up 140% YoY). Q2 FY26 Country Contributions: Germany: ₹400 crore (+23% YoY, +26% QoQ) UK: ₹160 crore (-4% YoY, -10% QoQ) Rest of Europe: ₹120 crore (+35% YoY, +6% QoQ) New Products: 8 new products were launched during the quarter. India Segment Performance (Q2 FY26): Q2 FY26 Revenues: ₹1,580 crore YoY Increase: 13% QoQ Increase: 7% H1 FY26 Revenues: ₹3,050 crore (+12% YoY). Drivers of Growth: Price increases, new launches, and higher volumes. New Brands: 11 new brands were launched in Q2 FY26 (taking the H1 total to 16).